Cytopharmaceuticals represent a new generation of biomaterials, consisting of cells engineered through genetic modification or chemical alterations to achieve specific biological functions or therapeutic effects, such as CAR-T cells. Despite significant advancements, traditional genetic engineering and chemical modification approaches are often complex, time-consuming, costly, and pose risks of cellular damage. This project employs bio-orthogonal, multi-point, supramolecular host-guest interactions to modify cells, pioneering a novel supramolecular chemistry-mediated cell engineering technology. This project leveraged innovative supramolecular self-assembly on cell membranes to load drugs and has developed a series of engineered cytopharmaceuticals mediated via supramolecular chemistry, enabling cellular functions based, targeted drug delivery or long-circulation drug release. Constructing cytopharmaceuticals using host-guest chemistry is a globally innovative technology that offers rapid, non-destructive, scalable process. This approach holds great promise for further advancement toward clinical research and applications.

Fig 1 Supramolecular chemistry mediated cell engineering technology for the preparation of novel cytopharmaceuticals for precise treatment of many diseases